Merck KGaA/€MRK
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
€MRK
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
62,604
Website
Merck KGaA Metrics
BasicAdvanced
€49B
17.53
€6.48
0.64
€2.20
1.94%
Price and volume
Market cap
€49B
Beta
0.64
52-week high
€174.45
52-week low
€102.10
Average daily volume
190K
Dividend rate
€2.20
Financial strength
Current ratio
1.306
Quick ratio
0.694
Long term debt to equity
23.293
Total debt to equity
34.352
Dividend payout ratio (TTM)
36.37%
Interest coverage (TTM)
17.86%
Profitability
EBITDA (TTM)
5,826.2
Gross margin (TTM)
59.39%
Net profit margin (TTM)
13.22%
Operating margin (TTM)
19.53%
Effective tax rate (TTM)
21.40%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
5.26%
Return on equity (TTM)
9.75%
Valuation
Price to earnings (TTM)
17.528
Price to revenue (TTM)
2.317
Price to book
1.65
Price to tangible book (TTM)
11
Price to free cash flow (TTM)
22.616
Free cash flow yield (TTM)
4.42%
Free cash flow per share (TTM)
501.99%
Dividend yield (TTM)
1.94%
Forward dividend yield
1.94%
Growth
Revenue change (TTM)
2.38%
Earnings per share change (TTM)
3.47%
3-year revenue growth (CAGR)
1.72%
10-year revenue growth (CAGR)
6.11%
3-year earnings per share growth (CAGR)
-4.03%
10-year earnings per share growth (CAGR)
9.73%
3-year dividend per share growth (CAGR)
5.95%
10-year dividend per share growth (CAGR)
8.20%
What the Analysts think about Merck KGaA
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Bulls say / Bears say
Merck KGaA's acquisition of SpringWorks Therapeutics for $3.9 billion enhances its rare cancer treatment portfolio, potentially driving future revenue growth. (reuters.com)
The company anticipates currency-adjusted operating earnings growth of up to 8% in 2025, supported by strong demand for semiconductor chemicals and laboratory equipment used in biotech drug production. (reuters.com)
Goldman Sachs initiated coverage on Merck KGaA with a 'Buy' rating and a price target of EUR205.00, citing a positive outlook for the company's Life Science sector recovery extending into 2025 and 2026. (investing.com)
Merck KGaA issued a more cautious earnings outlook for 2025 due to macroeconomic and geopolitical uncertainties, as well as foreign-exchange headwinds, adjusting its adjusted EBITDA forecast to €5.8 billion to €6.4 billion from the previous €6.1 billion to €6.6 billion. (reuters.com)
The company faces challenges from expiring drug patents, prompting the acquisition of SpringWorks Therapeutics to bolster its pipeline, indicating potential revenue declines from existing products. (reuters.com)
Merck KGaA's Life Science division, its largest business segment, is affected by ongoing concerns over tariffs, leading to a slight adjustment in guidance for this sector. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.
Merck KGaA Financial Performance
Revenues and expenses
Merck KGaA Earnings Performance
Company profitability
Merck KGaA News
AllArticlesVideos
Merck Animal Health announces $895 million investment in Kansas
Reuters·3 months ago
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
Business Wire·3 months ago
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merck KGaA stock?
Merck KGaA (MRK) has a market cap of €49B as of July 25, 2025.
What is the P/E ratio for Merck KGaA stock?
The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 17.53 as of July 25, 2025.
Does Merck KGaA stock pay dividends?
Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of July 25, 2025, the dividend rate is €2.2 and the yield is 1.94%. Merck KGaA has a payout ratio of 36.37% on a trailing twelve-month basis.
When is the next Merck KGaA dividend payment date?
The next Merck KGaA (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck KGaA?
Merck KGaA (MRK) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.